10x Genomics annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
10x Genomics's operating margin was −9.49% for fiscal 2025.
View full 10x Genomics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −9.49% | +22.37 pp |
| 2024 | 2024-12-31 | −31.85% | +11.03 pp |
| 2023 | 2023-12-31 | −42.88% | −10.36 pp |
| 2022 | 2022-12-31 | −32.52% | −21.87 pp |
| 2021 | 2021-12-31 | −10.65% | +168.08 pp |
| 2020 | 2020-12-31 | −178.74% | −166.30 pp |
| 2019 | 2019-12-31 | −12.43% | +63.27 pp |
| 2018 | 2018-12-31 | −75.70% | −49.85 pp |
| 2017 | 2017-12-31 | −25.85% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −12.95% | −30.37 pp |
| Q1 2026 | 2026-03-31 | −11.30% | +14.09 pp |
| Q4 2025 | 2025-12-31 | −11.77% | +18.43 pp |
| Q3 2025 | 2025-09-30 | −21.64% | +5.72 pp |
| Q2 2025 | 2025-06-30 | 17.42% | +44.68 pp |
| Q1 2025 | 2025-03-31 | −25.39% | +18.22 pp |
| Q4 2024 | 2024-12-31 | −30.20% | −0.20 pp |
| Q3 2024 | 2024-09-30 | −27.36% | +34.34 pp |
| Q2 2024 | 2024-06-30 | −27.26% | +15.89 pp |
| Q1 2024 | 2024-03-31 | −43.61% | −4.90 pp |
| Q4 2023 | 2023-12-31 | −30.00% | −15.21 pp |
| Q3 2023 | 2023-09-30 | −61.70% | −31.18 pp |
| Q2 2023 | 2023-06-30 | −43.15% | +11.92 pp |
| Q1 2023 | 2023-03-31 | −38.71% | −2.26 pp |
| Q4 2022 | 2022-12-31 | −14.78% | −3.75 pp |
| Q3 2022 | 2022-09-30 | −30.51% | −17.84 pp |
| Q2 2022 | 2022-06-30 | −55.07% | −46.16 pp |
| Q1 2022 | 2022-03-31 | −36.45% | −26.80 pp |
| Q4 2021 | 2021-12-31 | −11.03% | +353.96 pp |
| Q3 2021 | 2021-09-30 | −12.67% | +78.19 pp |
| Q2 2021 | 2021-06-30 | −8.92% | +82.96 pp |
| Q1 2021 | 2021-03-31 | −9.65% | +18.00 pp |
| Q4 2020 | 2020-12-31 | −364.99% | −354.26 pp |
| Q3 2020 | 2020-09-30 | −90.86% | −76.00 pp |
| Q2 2020 | 2020-06-30 | −91.88% | −73.31 pp |
| Q1 2020 | 2020-03-31 | −27.65% | −21.99 pp |
| Q4 2019 | 2019-12-31 | −10.73% | +30.06 pp |
| Q3 2019 | 2019-09-30 | −14.86% | — |
| Q2 2019 | 2019-06-30 | −18.56% | — |
| Q1 2019 | 2019-03-31 | −5.66% | — |
| Q3 2018 | 2018-09-30 | −40.79% | — |
Over the last five reported fiscal years, 10x Genomics's operating margin increased from −178.74% to −9.49%, a change of +169.25 percentage points. The latest reported quarter, Q2 2026, shows −12.95%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 10x Genomics filings at SEC.gov ↗